A retrospective study for infection among patients receiving Ibrutinib
Latest Information Update: 18 Dec 2020
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Leukaemia; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 18 Dec 2020 New trial record
- 25 Oct 2020 Results presented at the IDWeek 2020